Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.430
-0.150 (-9.49%)
At close: Sep 15, 2025, 4:00 PM EDT
1.350
-0.080 (-5.59%)
After-hours: Sep 15, 2025, 7:59 PM EDT
Cocrystal Pharma Employees
Cocrystal Pharma had 11 employees as of December 31, 2024. The number of employees decreased by 1 or -8.33% compared to the previous year.
Employees
11
Change (1Y)
-1
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$1,141,909
Market Cap
18.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | -1 | -8.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | 0 | - |
| Dec 31, 2020 | 13 | 2 | 18.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
COCP News
- 10 hours ago - Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 days ago - Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 days ago - Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference - GlobeNewsWire
- 7 days ago - Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment - GlobeNewsWire
- 12 days ago - Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 4 weeks ago - Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 5 weeks ago - Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference - GlobeNewsWire
- 2 months ago - Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference - GlobeNewsWire